SYN News and Press, Synthetic Biologics Inc. From 05/16/22

Synthetic Biologics press release (NYSE:SYN): Q1 GAAP EPS of -$0.03 in-line. As of March 31, 2022, the company reported $56.7M in cash, which is expected to provide runway through the end of 2023. For further details see: Synthetic Biologics GAAP EPS of -$0.03 in-line

-Encouraging data further supports the development of novel oncolytic adenovirus (OV) platform; Announced a peer-reviewed publication highlighting positive clinical data on VCN-01 and an upcoming oral presentation on VCN-11, a novel oncolytic adenovirus designed to evade neutralizing anti...

Synthetic Biologics (SYN) is scheduled to announce Q1 earnings results on Monday, May 16th, before market open. The consensus EPS Estimate is -$0.03 Over the last 3 months, EPS estimates have seen 0 upward revisions and 1 downward. For further details see: Synthetic Biologics Q1 2022 Ea...

BITF, CGEN, CLSN, CMRX, OTCQB:CVSI, GOED, KALA, LTRY, LUNA, MNMD, NOVN, OEG, PLX, PTE, SOHU, SSYS, SYN, SYRS, TCRT, WEJO, WIX, WRBY For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Monday's open

Synthetic Biologics (NYSE:SYN) said its oral drug SYN-020 was seen to be well tolerated across all doses in healthy people in an early stage study. The company reported data from a phase 1 multiple ascending dose (MAD) trial of SYN-020, a recombinant bovine intestinal alkaline phosphatas...

-Orally administered SYN-020 observed to be well tolerated across all doses in healthy volunteers- ROCKVILLE, Md., May 10, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseas...

ROCKVILLE, Md., May 09, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that it plans to host a conference call on Monday, May 16, 20...

ROCKVILLE, Md., May 05, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced the strengthening of its oncology leadership team with th...

- VCN-11 incorporates a proprietary albumin binding domain in the virus shell with the potential to improve systemic delivery and extend therapeutic efficacy through a multi-dosing strategy- - Data to be featured in an oral presentation on Monday, May 16 at 5:15 p.m. ET- ...

Has the stock market bottomed? That’s what some traders are weighing right now against a backdrop of new earnings data and Fed speak. Meanwhile, small-caps, micro-caps, and penny stocks remain a hot topic among retail traders. Other than their ability to record significant ga...